125 results about "Non specific" patented technology

The invention discloses an anti-CD3D antibody and application thereof.The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of CDR-H1 of the heavy chain variable region is shown as SEQ ID NO: 4, the amino acid sequence of CDR-H2 of the heavy chain variable region is shown as SEQ ID NO: 5, and the amino acid sequence of CDR-H3 of the heavy chain variable region is GDL; the amino acid sequence of the CDR-L1 of the light chain variable region is as shown in SEQ ID NO: 6, the amino acid sequence of the CDR-L2 of the light chain variable region is as shown in SEQ ID NO: 7, and the amino acid sequence of the CDR-L3 of the light chain variable region is as shown in SEQ ID NO: 8. The anti-CD3D antibody is a rabbit monoclonal antibody, the obtained antibody is high in titer, clear in specific positioning in immunohistochemical staining and free of non-specific background staining, the antibody is wide in application, and the antibody can be used in pathological immunohistochemical staining experiments and can also be used in Western blot and flow cytometry experiments.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

The invention relates to a primer probe combination, a kit, a method and application for detecting leprosy bacilli. The primer probe combination comprises six primers and a fluorescent probe combination. The combination of the six primers and the fluorescent probe has the advantages of high sensitivity and specificity when being used for detecting the leprosy bacilli, and the problem of false positive caused by non-specific amplification in the traditional LAMP detection is effectively solved. In addition, detection can be completed within 30 minutes, the reaction time is shorter, and the detection result is accurate. The HiFi-LAMP detection technology provides an effective and reliable scheme for leprosy diagnosis, is beneficial to early discovery and timely treatment of leprosy, and further makes a contribution to elimination of global leprosy.

A method and kit are provided for detecting anti-drug antibodies (ADAs) against self-assembling trimeric biologics, such as XPro1595, a pegylated variant of soluble human Tumor Necrosis Factor, in biological samples, particularly human serum. The method employs an Affinity Capture Elution-Protein A / G (ACE-AG) assay that overcomes non-specific reagent interactions inherent in conventional bridging and standard ACE assays due to the biologic's dynamic monomer exchange. The assay utilizes a two-plate system: a streptavidin-coated plate with biotinylated trimeric biologic captures ADAs, which are eluted, neutralized, and transferred to a protein A / G-coated plate for specific immunoglobulin capture and detection with a sulfo-tagged trimeric biologic via electrochemiluminescence. The kit includes pre-coated plates, labeled biologics, elution and neutralization solutions, assay buffer, confirmatory reagent, and instructions. The assay offers a robust, specific, and sensitive solution for immunogenicity testing of trimeric biologics.

Disclosed herein systems, processors, or computer-readable media configured with instructions to: receive transmission and / or reflection images of a tissue of a subject, wherein the images are generated from acoustic signals derived from acoustic waveforms transmitted through the tissue; provide a set of prognostic parameters associated with a user selected region of interest; wherein the set of prognostic parameters comprises sound propagation metrics characterizing sound propagation within a tissue; wherein the set of prognostic parameters corresponds to inputs into a tissue classifier model; wherein the set of prognostic parameters comprises a plurality of subsets of related feature groupings; and determine a type of tissue of the subject based on said plurality of subsets of related feature groupings using the classifier model, wherein the type of tissue is a cancerous tumor, a fibroadenoma, a cyst, a nonspecific benign mass, and an unidentifiable mass.

The invention discloses an ultrasensitive immunodetection method based on adjacent nucleic acid amplification signal amplification in the technical field of medical detection. The ultrasensitive immunodetection method comprises the following steps: step 1, immune binding; step 2, enzyme digestion release: releasing a hairpin loop DNA single strand; step 3, complementation and enzyme ligation: adding T4 ligase to cyclize the circular DNA single chain; step 4, rolling circle amplification; and step 6, detecting, and quantifying and positioning by qPCR (quantitative polymerase chain reaction) and an in-situ oligonucleotide fluorescence labeling detection method. According to the present invention, the hairpin ring structure on the oligonucleotide DNA chain coupled to the antibody protects the complementary sequence so as to avoid the generation of the non-specific circular DNA single chain, and the rolling circle amplification technology is combined to amplify the detection signal, such that the detection background signal intensity is inhibited while the specificity of the detection signal is enhanced so as to further improve the detection sensitivity.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The present application relates to the technical field of biomedicine, and in particular to a glutamate urea compound, a preparation method and a use thereof, a nuclide targeting probe, a preparation method and a use thereof, and a pharmaceutical composition. The glutamate urea compound and the nuclide targeting probe provided by the present application have excellent in vivo biological properties, high specific uptake in lesions having high PSMA protein expression, high target-to-non-target ratio, low non-specific background activity, and significantly enhanced tumor uptake and retention time, are suitable for use as nuclide treatment and imaging of tumors, can also reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects of relatively low target organ uptake and excessively short retention time of small molecules acting on PSMA, exhibit improved targeted PSMA nuclide treatment and imaging effects, and have the potential for clinical promotion and application.

The invention relates to the technical field of biomedical treatment, in particular to a primer probe combination for distinguishing and relatively quantifying wild type and secondary drug-resistant mutation of EGFR (Epidermal Growth Factor Receptor) genes. The ARMS PCR primer probe combination, the detection reagent, the kit and the detection method which take the EGFR gene as the target are obtained by optimizing the mutation site position and concentration of the primer probe and screening the annealing temperature and enzyme. The primer probe combination, the detection reagent, the kit and the detection method disclosed by the invention are used for ARMS PCR detection of EGFR genes, the amplification inhibition capability on a wild type template is improved, non-specific amplification is reduced to improve specificity, and meanwhile, a good linear relationship can be kept; the primer design process is simplified, and introduction of extra mismatched bases is avoided; a reliable relative quantitative system is established, experimental interference factors are eliminated, and abundance of mutant genes is accurately reflected; the detection period is shortened, the cost is reduced, clinical rapid detection requirements are met, and a more reliable technical means is provided for detection of mutant genes.

The present invention relates to the technical field of biomedicine, and particularly relates to a glutamic acid urea compound and a preparation method therefor and a use thereof, a nuclide targeting probe and a preparation method therefor and a use thereof, and a pharmaceutical composition. The glutamic acid urea compound and the nuclide targeting probe provided by the present invention have excellent in-vivo biological performance, high specific uptake in lesions with high expression of PSMA protein, a high target-nontarget ratio, low non-specific background activity, and remarkably enhanced tumor uptake and retention time, are suitable for nuclide therapy and imaging of tumors, can reduce unnecessary radioactive damage to normal tissues and organs, can overcome the defects of low uptake and short retention time in small-molecule PSMA targeting organs, improve the PSMA targeting nuclide treatment and imaging effects, and have the potential of clinical popularization and application.

According to the DUX4-IGH rearrangement detection primer probe set, the kit and the application, common rearrangement fracture sites of DUX4-IGH are confirmed, an upstream primer is designed on the upstream of a DUX4 transcript, 33 downstream primers are designed according to IGH fracture positions, a universal primer is designed on the upstream of DUX4, and a universal DUX4 probe is designed near the downstream of the primer; interference between the primer probes is small, influence of non-specific amplification is small, the primer probes are suitable for specific detection of multiple DUX4-IGH rearrangement sites, the problem that rearrangement detection is difficult in the prior art is solved, DUX4-IGH fusion transcripts and ABL1 reference genes can be quantitatively detected in a digital PCR instrument through RT-PCR, a basis is provided for auxiliary diagnosis, and the primer probes have remarkable application prospects.

The present invention relates to the technical field of biological virus detection, and specifically discloses primers and probes for specifically detecting Cyprinid herpesvirus 2 and their applications. Among the primers and probes for detecting Cyprinid herpesvirus 2, the sequence of the inner primer FIP is as shown in SEQ ID NO:1, the sequence of the inner primer BIP is as shown in SEQ ID NO:2, the sequence of the outer primer F3 is as shown in SEQ ID NO:3, the sequence of the outer primer B3 is as shown in SEQ ID NO:4, and the sequence of the loop primer probe is as shown in SEQ ID NO:5. By using the primers and probes of the present invention, the accurate detection of Cyprinid herpesvirus 2 can be achieved, the appearance of false positive results caused by non-specific amplification can be avoided, and the lowest detection limit can reach 0.5 copies / μL, which is more conducive to the early detection of Cyprinid herpesvirus 2, thereby avoiding the spread of diseases, and has very important significance for the prevention and control of aquatic diseases.

Disclosed herein systems, processors, or computer-readable media configured with instructions to: receive transmission and / or reflection images of a tissue of a subject, wherein the images are generated from acoustic signals derived from acoustic waveforms transmitted through the tissue; provide a set of prognostic parameters associated with a user selected region of interest; wherein the set of prognostic parameters comprises sound propagation metrics characterizing sound propagation within a tissue; wherein the set of prognostic parameters corresponds to inputs into a tissue classifier model; wherein the set of prognostic parameters comprises a plurality of subsets of related feature groupings; and determine a type of tissue of the subject based on said plurality of subsets of related feature groupings using the classifier model, wherein the type of tissue is a cancerous tumor, a fibroadenoma, a cyst, a nonspecific benign mass, and an unidentifiable mass.

This invention provides a respiratory compensation early warning method and system based on multi-modal behavioral evolution recognition, comprising: continuously acquiring patient behavioral posture data; analyzing the behavioral posture data based on a predefined behavioral evolution knowledge base to identify whether there is a type I posture or a type II posture, wherein the type I posture is a high-frequency non-specific posture that exceeds the individual baseline, and the type II posture is a specific compensatory posture that conforms to a preset specific physiological definition; analyzing the temporal correlation between type I and type II postures, and generating a high-confidence early warning signal if an evolution from type I posture to type II posture is identified. This invention achieves a digital closed loop of clinical cognition: for the first time, it transforms the complete clinical cognition of medical staff—"the patient first becomes restless, then becomes short of breath and sits up"—into a calculable and predictable technical model, which is highly consistent with clinical thinking and easily trusted.

The present invention belongs to the field of biotechnology, and particularly relates to a marker, a primer set, a highly sensitive and highly specific kit and a detection method for detecting urothelial carcinoma. The present invention avoids nonspecific amplification by reselecting markers, designing primers and probes; then, by adjusting the concentration ratio of primers and probes and the PCR reaction conditions, by setting a positive threshold and three repeated experiments based on the minimum detection limit study, the developed detection kit is tested in 80 UC and 130 non-cancer individuals. The results show that the sensitivity is as high as 97.5% and the specificity is as high as 96.9%. Compared with existing products, the sensitivity and specificity are significantly improved, and it is more suitable for clinical auxiliary diagnosis and population screening than existing products.

The invention relates to the technical field of molecular biological detection, in particular to a primer probe group and a kit for simultaneously detecting 21 respiratory tract pathogens in a sample and application of the primer probe group and the kit. The primer probe group comprises primer probe sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 75. The primer probe group comprises primer probe sequences as shown in SEQ ID NO. According to the kit, 21 respiratory tract pathogens are detected through seven groups of detection, the total time consumption is about 45 minutes per batch, the detection time is shortened, and the kit has excellent specificity and no non-specific amplification and better meets the requirements of outpatient emergency treatment and fever outpatient service for rapid diagnosis.

The invention relates to the field of gene detection, and discloses a detection primer of an atherosclerosis related SNP (Single Nucleotide Polymorphism) site rs759080989 and application of the detection primer. The detection primer of the atherosclerosis related SNP site rs759080989 comprises two non-specific outer side primers and two inner side primers for specifically detecting an SNP mutation site, the two outer side primers have sequences as shown in SEQ ID NO: 1 and SEQ ID NO: 2 or complementary sequences of the sequences, and the two inner side primers have sequences as shown in SEQ ID NO: 3 and SEQ ID NO: 4 or complementary sequences of the sequences. According to the detection primer and the application design thereof, the primer which is based on the ARMS-PCR method and is specifically matched with the rs759080989 site is verified, a reaction system and reaction conditions are perfected, amplification and detection of a target gene are successfully completed, and the positive significance is achieved for clinic.

The present invention relates to the field of biological detection technology, and in particular to a detection kit and method for eliminating nonspecific reactions in blood samples. The present invention provides a detection kit comprising a first reagent and a second reagent; the first reagent comprises a buffer solution, 0.01-0.5wt% sodium alginate, 0.05-1wt% nonionic surfactant, and 0.001-0.1wt% animal serum; the pH value of the first reagent buffer system is 7.2-7.4; the second reagent comprises an antibody buffer solution labeled with latex microspheres; the pH value of the second reagent buffer system is 7.8-8.0. The present invention provides a detection kit and its application, which can effectively eliminate the interference of nonspecific reactions on the detection results of biochemical indicators by using latex immunoturbidimetry to detect biochemical indicators in serum and plasma, thereby improving the accuracy of the detection results of biochemical indicators.

The invention relates to the technical field of novel drug application of compounds, in particular to a compound Man-Tz, a biological orthogonal reaction system and application of the compound Man-Tz. The dTRIM24 is accurately released at the atherosclerotic plaque through a biological orthogonal targeting technology, and the problem of non-specific distribution caused by a traditional administration mode is effectively solved by utilizing the specific reaction of an artificial target point Man-Tz and TCO-dTRIM24-TCO. According to the technology, the TRIM24 protein of 117kDa can be specifically degraded, and macrophages are promoted to be polarized to an anti-inflammatory M2 type by inhibiting Stat6 acetylation, so that plaque formation is inhibited. Experiments prove that the system has concentration and time-dependent effects, drug exposure of non-target tissues is remarkably reduced while efficient degradation activity is maintained, and a novel targeted therapy strategy with high specificity and low toxic and side effects is provided for atherosclerosis treatment.

The invention belongs to the technical field of animal pathogen molecular biology, and particularly relates to a dual quantitative fluorescent primer probe composition, a kit and an identification method for identifying hog cholera virus. Aiming at the current popular strains covering 3 genotypes, 11 gene subtypes and the like of the hog cholera gene, the invention selects 5UTR and NS3 gene sequences of hog cholera virus to design and synthesize specific primers and probes aiming at the two fragments; the specific primer has no non-specific amplification on African swine fever virus, pseudorabies virus, porcine reproductive and respiratory syndrome virus, porcine circovirus type II, porcine epidemic diarrhea and bovine viral diarrhea. The invention establishes a method for identifying the classical swine fever virus wild strain and the vaccine strain and develops a kit convenient for diagnosis, and the kit and the identification method can simultaneously identify the classical swine fever virus wild strain and the vaccine strain, have the characteristics of high sensitivity, strong specificity, good repeatability and good stability, and have extremely strong application prospects.

This invention relates to the field of biological detection, and more particularly to a monoclonal antibody combination for detecting human IL-8 protein and its application. The combination comprises monoclonal antibodies 2G3 and 3H8. The heavy and light chain variable regions of monoclonal antibody 2G3 include the complementarity-determining regions shown in SEQ ID NO. 1-6; the heavy and light chain variable regions of monoclonal antibody 3H8 include the CDRs shown in SEQ ID NO. 7-12. The antibody combination of this invention exhibits high specificity and effectively avoids cross-reactivity with other CXC chemokine family members, thereby significantly reducing non-specific background interference and the risk of false positives during detection. This invention provides a high-performance, quality-controllable key tool for biological detection for non-diagnostic purposes, research on inflammatory mechanisms, and the development of related scientific reagents.

The invention provides high-specificity immunochromatography test paper as well as a preparation method and application thereof, and relates to the technical field of biological detection, the high-specificity immunochromatography test paper sequentially comprises a sample pad, a blood filtering pad and a combination pad which are lapped on a bottom plate in the chromatography direction; the blood filtering pad contains a pretreatment reagent, the pretreatment reagent comprises an anti-human RBC antibody, Tween-20 and bovine serum albumin, a blood filtering pad assembly is added between the combination pad and the detection pad of the immunochromatography test paper, and the blood filtering pad contains the pretreatment reagent, namely the anti-human RBC antibody, Tween-20 and bovine serum albumin, so that a sample is filtered to remove interfering substances; the reaction is homogenized; data show that the membrane surface background is free of redness, clean and free of interference in blood screen item detection, high specificity of products is guaranteed, and blocking agents are not used. The technical problem that nonspecific interference of an immunoreaction inhibitor is generated by using a blocking agent in immunochromatography test paper in the prior art is solved.

The invention provides a primer probe combination and a portable kit for African swine fever pathogen detection, and relates to the technical field of biological detection. The primer probe combination comprises an upstream primer, a downstream primer and a probe, the nucleotide sequence of the upstream primer is as shown in SEQ ID NO.7; the nucleotide sequence of the downstream primer is as shown in SEQ ID NO.8; and the nucleotide sequence of the probe is as shown in SEQ ID NO. 9. The primer probe combination adopts a specific sequence obtained by screening SEQ ID NO.7-9, the detection sensitivity reaches 1 copies / T, and non-specific amplification is avoided. Through double labeling of biotin and a fluorophore and modification of tetrahydrofuran and a blocking group, the group is suitable for isothermal amplification and lateral chromatography technologies, visual color development of a specific amplification product can be realized without a variable-temperature instrument, and the group is suitable for low-cost field rapid detection.

The present application relates to the technical field of clinical in vitro detection reagent, especially relates to reagent combination and its application in eliminating MALB reagent non-specific interference detection. When MALB reagent is calibrated at 0 point with purified water, and normal human urine sample is tested on a biochemical instrument, the test value can be 0 or negative, especially when the concentration of urine is 0 mg / L-5 mg / L, the test value is basically 0. The present application selects suitable Malb antibody and suitable antibody feeding amount to improve the sensitivity of reagent, and selects suitable background solution in the reaction system to reduce the non-specific interference of MALB reagent. Not only the problem of 0 or negative sample value is effectively improved, but also the detection accuracy is improved, which has important significance for improving the accuracy of MALB reagent test sample. The reagent combination provided by the present application has good clinical application and large-scale industrial production prospect.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The present invention discloses a PET imaging agent targeting PD-L1, its preparation method and application. The PET imaging agent of the present invention is obtained by modifying the Durva-F(ab')2 antibody fragment with an acylating agent 3-(4-hydroxyphenyl)propionic acid-N-succinimide ester, and then 124 labeling with 124 I to obtain the I-HPP-Durva-F(ab')2 polypeptide molecular probe. By subjecting the modified Durva-F(ab')2 antibody fragment obtained in the present invention to SHPP amidation modification, the blood clearance rate and labeling specific activity of the probe are improved. The molecular probe of the present invention has a significantly reduced molecular weight, which accelerates the clearance rate of the probe in vivo and is beneficial to clinical translation. The non-specific uptake of this molecular probe in the liver and bone tissues is significantly reduced, which has great clinical significance for patients whose metastases or primary lesions are located in this part.

The present application relates to the technical field of bioinformatics and drug evaluation, and particularly relates to a method for constructing an organoid drug sensitivity evaluation model based on multi-omics fusion, comprising synchronously collecting morphokinetic time sequence images and multi-time point single-cell multi-omics data of organoids, obtaining paired morphological and molecular dynamic data, extracting cell state factors through coupled non-negative tensor decomposition, constructing a non-equilibrium free energy landscape under drug disturbance, quantifying the loss degree of molecular system robustness from two dimensions of geometric deformation and topological structure, detecting cross-scale causal relationships and constructing a drug disturbance entropy index. In the present application, the drug effect is evaluated from the physical nature of the loss of biological system robustness, replacing the traditional correlation analysis method, realizing the unification of quantitative evaluation of drug sensitivity and explanation of the mechanism of action, effectively distinguishing drug specific action and non-specific stress, and being suitable for personalized tumor treatment and new drug research and development.

The invention discloses a novel Fc effect eliminated framework flow antibody, and belongs to the technical field of biological medicine. The antibody comprises a mutation combination of L234A, L235A, P238S and D265A in a heavy chain CH2 region, and can further comprise S267E and L328F mutations, so that the Fc receptor binding capacity is effectively reduced. The type of the antibody can be selected from multiple forms of scFv-Fc, (scFv) 2-Fc, scFv / scFv-Fc, Fab / scFv-Fc and the like. The invention also provides a nucleic acid sequence for coding the antibody and a preparation method of the antibody. The preparation method comprises the following steps: introducing specific mutation into a CH2 region of recombinant rabbit IgG, and expressing and purifying in a mammal expression system to obtain the antibody. When the antibody is applied to a flow cytometry detection reagent, a non-specific background signal caused by Fc receptor combination can be effectively eliminated, and the detection specificity and accuracy are improved.

The application provides a prognosis risk stratification prediction method for lymph node tumor residue, and belongs to the technical field of risk prediction, and comprises the following steps: acquiring lymph node HE staining sections and immunohistochemical labeling sections, automatically identifying a tumor region of interest by using a U-Net++ network, removing background noise and non-specific staining interference based on a self-adaptive threshold segmentation algorithm, extracting information in four dimensions, and forming a standardized extracted information set; fusing and mapping the extracted information set into a 256-dimensional feature vector set, inputting each vector into a dynamic integrated prediction model, and outputting stratified differential expression of each vector and stratified comprehensive expression of the vector set; determining a risk level based on quantitative threshold values of the stratified differential expression and comparative analysis of risk probabilities of the stratified comprehensive expression, and constructing a multi-dimensional dynamic weight decision model in combination with patient self-state indexes to formulate a personalized scheme. Through multi-modal feature extraction, dynamic integrated modeling and personalized decision-making, precise risk stratification and treatment scheme customization are realized.

The present invention discloses a nano-boron delivery agent and its preparation method and application. The nano-boron delivery agent h-10BN-PG nanoparticles provided by the present invention have the characteristics of being easy to prepare, non-toxic, good biocompatibility, high 10B content, good dispersibility and stability in physiological solutions, etc. The h-10BN-PG nanoparticles can inhibit protein adsorption and non-specific uptake by macrophages, and have good "stealth" characteristics, thus avoiding rapid clearance by the MPS, and their blood circulation time is up to 8.5 hours. The h-10BN-PG nanoparticles can accumulate efficiently in CT26 tumor tissues through the EPR effect and can be further endocytosed by tumor cells; the concentration of 10B in tumors can reach 8.8% ID / g or 102.1 ppm. BNCT mediated by h-10BN-PG nanoparticles can completely eradicate subcutaneous CT26 tumors with only one injection of nanoparticles and one neutron irradiation.